Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):306-13. doi: 10.1016/j.ijrobp.2010.06.025. Epub 2010 Oct 1.
To evaluate the potential for dose escalation with intensity-modulated radiotherapy (IMRT) in positron emission tomography-based radiotherapy planning for locally advanced non-small-cell lung cancer (LA-NSCLC).
For 35 LA-NSCLC patients, three-dimensional conformal radiotherapy and IMRT plans were made to a prescription dose (PD) of 66 Gy in 2-Gy fractions. Dose escalation was performed toward the maximal PD using secondary endpoint constraints for the lung, spinal cord, and heart, with de-escalation according to defined esophageal tolerance. Dose calculation was performed using the Eclipse pencil beam algorithm, and all plans were recalculated using a collapsed cone algorithm. The normal tissue complication probabilities were calculated for the lung (Grade 2 pneumonitis) and esophagus (acute toxicity, grade 2 or greater, and late toxicity).
IMRT resulted in statistically significant decreases in the mean lung (p <.0001) and maximal spinal cord (p = .002 and 0005) doses, allowing an average increase in the PD of 8.6-14.2 Gy (p ≤.0001). This advantage was lost after de-escalation within the defined esophageal dose limits. The lung normal tissue complication probabilities were significantly lower for IMRT (p <.0001), even after dose escalation. For esophageal toxicity, IMRT significantly decreased the acute NTCP values at the low dose levels (p = .0009 and p <.0001). After maximal dose escalation, late esophageal tolerance became critical (p <.0001), especially when using IMRT, owing to the parallel increases in the esophageal dose and PD.
In LA-NSCLC, IMRT offers the potential to significantly escalate the PD, dependent on the lung and spinal cord tolerance. However, parallel increases in the esophageal dose abolished the advantage, even when using collapsed cone algorithms. This is important to consider in the context of concomitant chemoradiotherapy schedules using IMRT.
评估在正电子发射断层扫描(PET)指导的放射治疗计划中,调强放疗(IMRT)在局部晚期非小细胞肺癌(LA-NSCLC)中的剂量递增潜力。
对 35 例 LA-NSCLC 患者进行了三维适形放疗和 IMRT 计划,处方剂量(PD)为 66 Gy/2 Gy。通过对肺、脊髓和心脏的次要终点约束来进行剂量递增,然后根据定义的食管耐受情况进行剂量递减。剂量计算使用 Eclipse 铅笔束算法,所有计划均使用锥形束算法重新计算。计算了肺(2 级肺炎)和食管(急性毒性,2 级或更高,和晚期毒性)的正常组织并发症概率。
IMRT 导致平均肺(p <.0001)和最大脊髓(p =.002 和 0.0005)剂量的统计学显著降低,允许 PD 平均增加 8.6-14.2 Gy(p ≤.0001)。在限定的食管剂量限制内进行剂量递减后,这种优势就丧失了。即使在剂量递增后,IMRT 也显著降低了肺的正常组织并发症概率(p <.0001)。对于食管毒性,IMRT 显著降低了低剂量水平的急性 NTCP 值(p =.0009 和 p <.0001)。在最大剂量递增后,晚期食管耐受变得至关重要(p <.0001),尤其是在使用 IMRT 时,因为食管剂量和 PD 的平行增加。
在 LA-NSCLC 中,IMRT 提供了显著增加 PD 的潜力,这取决于肺和脊髓的耐受程度。然而,食管剂量的平行增加消除了这种优势,即使使用锥形束算法也是如此。这在使用 IMRT 的同步放化疗方案中是需要考虑的重要因素。